BNGO Logo.jpg
Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research
February 02, 2023 08:00 ET | Bionano Genomics
Over 3,000 registrants with attendees from 114 countriesAverage daily attendance of 750 in 2023 versus 565 in 202231 oral presentations delivered across four consecutive days69 scientific posters...
BNGO Labs Logo
Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies
January 24, 2023 08:00 ET | Bionano Genomics
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of...
BNGO Logo.png
Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow
January 23, 2023 08:01 ET | Bionano Genomics
Bionano Prep SP-G2 (SP-G2) kit offers higher gDNA quality, improved ease-of-use and increased DNA throughputBionano Prep Direct Label and Stain-G2 (DLS-G2) kit offers increased reagent stability and...
BNGO Logo.png
Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications
January 20, 2023 08:00 ET | Bionano Genomics
27 different customers representing North America and Europe30 oral presentations across four consecutive days34 scientific posters will be featured in a virtual exhibition hallTopics span the...
BNGO Logo.png
Bionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing
January 18, 2023 08:00 ET | Bionano Genomics
IRB-approved, multi-site, ongoing study evaluated 200 samples representing 123 unique prenatal cases across 9 sites for interim measures of key endpoints: Results of OGM analysis were comparable, in...
BNGO Logo.png
Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
January 12, 2023 08:00 ET | Bionano Genomics
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome...
BNGO Logo.png
Bionano Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer
January 11, 2023 08:00 ET | Bionano Genomics
SAN DIEGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study analyzing optical genome mapping (OGM) as a method to identify...
BNGO Logo.png
Bionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications
January 10, 2023 08:00 ET | Bionano Genomics
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to...
BNGO Logo.png
Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
January 06, 2023 08:00 ET | Bionano Genomics
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in...
BNGO Logo.png
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
January 05, 2023 08:00 ET | Bionano Genomics
- Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021- Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021- Achieved or...